78 related articles for article (PubMed ID: 35609865)
1. Outcomes of hematopoietic cell transplantation for diffuse large B cell lymphoma transformed from follicular lymphoma.
Wirk B; Fenske TS; Hamadani M; Zhang MJ; Hu ZH; Akpek G; Aljurf MD; Armand P; Ayala E; Bachanova V; Bolwell B; Cairo MS; Cashen A; Chen YB; Costa LJ; Farhan S; Freytes CO; Gajewski JL; Gibson J; Hale GA; Holmberg LA; Hsu JW; Inwards DJ; Kamble RT; Maharaj D; Maziarz RT; Munker R; Nath R; Reddy NM; Reeder CB; Rizzieri DA; Sauter CS; Savani BN; Schouten HC; Sureda A; Vose JM; Waller EK; Wiernik PH; Gale RP; Burns LJ; Saber W
Biol Blood Marrow Transplant; 2014 Jul; 20(7):951-9. PubMed ID: 24641828
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphoma.
Furqan F; Ahn KW; Chen Y; Kaur M; Abutalib SA; Ahmed N; Ahmed S; Kharfan-Dabaja MA; Friedberg J; Gregory T; Hill L; Sterling C; Barta SK; Shadman M; Perales MA; Zain J; Herrera AF; Sauter C; Hamadani M
Br J Haematol; 2023 Jan; 200(1):54-63. PubMed ID: 36120837
[TBL] [Abstract][Full Text] [Related]
3. Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission.
Shadman M; Pasquini M; Ahn KW; Chen Y; Turtle CJ; Hematti P; Cohen JB; Khimani F; Ganguly S; Merryman RW; Yared JA; Locke FL; Ahmed N; Munshi PN; Beitinjaneh A; Reagan PM; Herrera AF; Sauter CS; Kharfan-Dabaja MA; Hamadani M
Blood; 2022 Mar; 139(9):1330-1339. PubMed ID: 34570879
[TBL] [Abstract][Full Text] [Related]
4. Impact of thiotepa dose-intensity in primary diffuse large B-cell lymphoma of the central nervous system undergoing autologous hematopoietic cell transplant with thiotepa/carmustine conditioning.
Arshad S; Fang X; Ahn KW; Kaur M; Scordo M; Sauter CS; Furqan F; Awan FT; Hamadani M
Bone Marrow Transplant; 2023 Nov; 58(11):1203-1208. PubMed ID: 37563283
[TBL] [Abstract][Full Text] [Related]
5. Autologous stem cell transplantation for post-transplant lymphoproliferative disorders after solid organ transplantation: a retrospective analysis from the Lymphoma Working Party of the EBMT.
Eyre TA; Caillard S; Finel H; Boumendil A; Kothari J; Zimmermann H; Trappe RU; De Wilde V; Tholouli E; Kanfer E; Broom A; Damaj G; Bargetzi M; Kozák T; Hilgendorf I; Crawley C; Kerre T; Trněný M; Bachy E; Robinson S; Montoto S
Bone Marrow Transplant; 2021 Sep; 56(9):2118-2124. PubMed ID: 33864020
[TBL] [Abstract][Full Text] [Related]
6. Outcomes and Utilization Trends of Front-Line Autologous Hematopoietic Cell Transplantation for Mantle Cell Lymphoma.
Riedell PA; Hamadani M; Ahn KW; Litovich C; Murthy GSG; Locke FL; Brunstein CG; Merryman RW; Stiff PJ; Pawarode A; Nishihori T; Kharfan-Dabaja MA; Herrera AF; Sauter CS; Smith SM
Transplant Cell Ther; 2021 Nov; 27(11):911.e1-911.e7. PubMed ID: 34450333
[TBL] [Abstract][Full Text] [Related]
7. Comorbidities, Alcohol Use Disorder, and Age Predict Outcomes after Autologous Hematopoietic Cell Transplantation for Lymphoma.
Graf SA; Vaughn JE; Chauncey TR; Storer BE; Gopal AK; Holmberg LA; McCune JS; Bensinger WI; Maloney DG; Press OW; Storb R; Sorror ML
Biol Blood Marrow Transplant; 2016 Sep; 22(9):1582-1587. PubMed ID: 27311969
[TBL] [Abstract][Full Text] [Related]
8. The association of body composition and outcomes following autologous hematopoietic stem cell transplantation in patients with non-Hodgkin lymphoma.
Aleixo GFP; Wei W; Chen PH; Gandhi NS; Anwer F; Dean R; Hamilton BK; Hill BT; Jagadeesh D; Khouri J; Pohlman B; Sobecks R; Winter A; Caimi P; Majhail NS
Bone Marrow Transplant; 2023 Dec; 58(12):1384-1389. PubMed ID: 37699993
[TBL] [Abstract][Full Text] [Related]
9. Auto-HCT May Be Best after Chemo in DLBCL.
Cancer Discov; 2023 Dec; ():OF1. PubMed ID: 38091574
[TBL] [Abstract][Full Text] [Related]
10. Clonal hematopoiesis in the setting of hematopoietic cell transplantation.
Gibson CJ; Lindsley RC; Gondek LP
Semin Hematol; 2024 Feb; 61(1):9-15. PubMed ID: 38429201
[TBL] [Abstract][Full Text] [Related]
11. New treatment options in elderly patients with Diffuse Large B-cell Lymphoma.
Arcari A; Cavallo F; Puccini B; Vallisa D
Front Oncol; 2023; 13():1214026. PubMed ID: 37465115
[TBL] [Abstract][Full Text] [Related]
12. CAR T-cell therapy has comparable efficacy with autologous transplantation in older adults with DLBCL in partial response.
Akhtar OS; Cao B; Wang X; Torka P; Al-Jumayli M; Locke FL; Freeman CL
Blood Adv; 2023 Oct; 7(19):5937-5940. PubMed ID: 37236167
[No Abstract] [Full Text] [Related]
13. Outcomes of Autologous Hematopoietic Cell Transplantation in Older Patients with Diffuse Large B-Cell Lymphoma.
Munshi PN; Chen Y; Ahn KW; Awan FT; Cashen A; Shouse G; Shadman M; Shaughnessy P; Zurko J; Locke FL; Goodman AM; Bisneto JCV; Sauter C; Kharfan-Dabaja MA; Meyers G; Jaglowski S; Herrera A; Hamadani M
Transplant Cell Ther; 2022 Aug; 28(8):487.e1-487.e7. PubMed ID: 35609865
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation.
Jagadeesh D; Majhail NS; He Y; Ahn KW; Litovich C; Ahmed S; Aljurf M; Bacher U; Badawy SM; Bejanyan N; Cairo M; Cerny J; Epperla N; Farhadfar N; Freytes CO; Gale RP; Haverkos B; Hossain N; Inwards D; Kamble RT; Kenkre VP; Lazarus HM; Lazaryan A; Lekakis L; Mei M; Murthy HS; Mussetti A; Nathan S; Nishihori T; Olsson RF; Ramakrishnan Geethakumari P; Savani BN; Yared JA; Fenske TS; Kharfan-Dabaja MA; Sureda A; Hamadani M
Cancer; 2020 May; 126(10):2279-2287. PubMed ID: 32049359
[TBL] [Abstract][Full Text] [Related]
15. Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation.
Hamadani M; Hari PN; Zhang Y; Carreras J; Akpek G; Aljurf MD; Ayala E; Bachanova V; Chen AI; Chen YB; Costa LJ; Fenske TS; Freytes CO; Ganguly S; Hertzberg MS; Holmberg LA; Inwards DJ; Kamble RT; Kanfer EJ; Lazarus HM; Marks DI; Nishihori T; Olsson R; Reddy NM; Rizzieri DA; Savani BN; Solh M; Vose JM; Wirk B; Maloney DG; Smith SM; Montoto S; Saber W; Alpdogan O; Cashen A; Dandoy C; Finke R; Gale R; Gibson J; Hsu JW; Janakiraman N; Laughlin MJ; Lill M; Cairo MS; Munker R; Rowlings PA; Schouten HC; Shea TC; Stiff PJ; Waller EK
Biol Blood Marrow Transplant; 2014 Nov; 20(11):1729-36. PubMed ID: 25008330
[TBL] [Abstract][Full Text] [Related]
16. R-BEAM versus Reduced-Intensity Conditioning Regimens in Patients Undergoing Allogeneic Stem Cell Transplantation for Relapsed Refractory Diffuse Large B Cell Lymphoma.
Modi D; Kim S; Surapaneni M; Ayash L; Alavi A; Ratanatharathorn V; Deol A; Uberti JP
Biol Blood Marrow Transplant; 2020 Apr; 26(4):683-690. PubMed ID: 31682979
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic hematopoietic cell transplantation for diffuse large B cell lymphoma: who, when and how?
Klyuchnikov E; Bacher U; Kroll T; Shea TC; Lazarus HM; Bredeson C; Fenske TS
Bone Marrow Transplant; 2014 Jan; 49(1):1-7. PubMed ID: 23708703
[TBL] [Abstract][Full Text] [Related]
18. Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet?
Epperla N; Fenske TS; Lazarus HM; Hamadani M
Bone Marrow Transplant; 2015 Nov; 50(11):1393-404. PubMed ID: 26281033
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
